RxDoctor Payments Data

Ricardo Gonzales, MD

Neurology · Sarasota, FLNPI 1063678035

Payments from drug & device makers

$106,171in general payments, 2019–2025

Across 664 payments — averaging $159.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$87K
  • Acadia Pharmaceuticals Inc$9K
  • AbbVie$2K
  • Abbott$624
  • Pfizer$576
  • Amgen$560
  • plus $6K from 43 others

What the payments were for

  • Consulting fees$6101%
  • Speaking & faculty fees$81,46084%
  • Travel & lodging$1,2891%
  • Food & beverage$13,55014%
  • Education$610%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$106,171 in reported general payments places this provider in the 85th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$586,886
Medicare patients
1,533
Services billed
16,095

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine45$265,065
AustedoDeutetrabenazine33$242,118
NuplazidPimavanserin Tartrate42$228,269
RytaryCarbidopa/Levodopa84$145,591
GocovriAmantadine Hcl39$123,562
NeuproRotigotine59$74,080
InbrijaLevodopa19$73,974
Rasagiline Mesylate328$53,224
Nurtec OdtRimegepant Sulfate25$24,795
Aimovig AutoinjectorErenumab-Aooe22$20,171
Emgality PenGalcanezumab-Gnlm23$19,055
UbrelvyUbrogepant14$16,075
Carbidopa-LevodopaCarbidopa/Levodopa749$13,983
BotoxOnabotulinumtoxina11$11,896
Memantine Hcl260$10,431

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$86,927$507,18378 claims
Acadia Pharmaceuticals IncNuplazid$9,384$228,26942 claims
Amneal Pharmaceuticals LLCRytary$163$145,59184 claims
MDD US Operations, LLCGocovri$414$123,56239 claims
UCB, Inc.Neupro$449$74,08059 claims
Acorda Therapeutics, IncInbrija$517$73,97419 claims
AbbVieUbrelvy, Botox$1,789$27,97125 claims
PfizerNurtec Odt$576$24,79525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,434 neurology providers in Florida.

Other neurology in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →